Skip to main content

Recombinant Human CD38 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10920-AC

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
10920-AC-020

Key Product Details

Source

HEK293

Accession #

Conjugate

Unconjugated

Applications

Enzyme Activity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human CD38 protein
Human CD38
(Val43-Ile300)
Accession # P28907.2
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Val43

Predicted Molecular Mass

57 kDa

SDS-PAGE

67-74 kDa, under reducing conditions

Activity

Measured by its ability to convert the substrate nicotinamide guanine dinucleotide (NGD+) to cyclic GDP-ribose. Graeff, R.M. et al. (1994) J. Biol. Chem. 269:30260.
The specific activity is >900 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human CD38 Fc Chimera Protein, CF

Recombinant Human CD38 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human CD38 Fc Chimera Protein (Catalog # 10920-AC) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 67-74 kDa and 130-150 kDa, respectively.

Formulation, Preparation and Storage

10920-AC
Formulation Supplied as a 0.2 μm filtered solution in MES and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: CD38

CD38, also known as ADP-ribosyl cyclase, converts NAD(P)+ into three separate products with calcium mobilizing ability: cyclic ADP-ribose, NAADP+, and ADP-ribose (1). CD38 is a Type II transmembrane glycoprotein composed of an intracellular domain, a single transmembrane helix domain, and a large extracellular domain that contains the catalytic site (2). CD38 is expressed in B and T lymphocytes, osteoclasts, and in cardiac, pancreatic, liver and kidney cells (3,4). Through its production of cyclic ADP-ribose, CD38 modulates calcium-mediated signal transduction in many types of cells (5,6). CD38 is also reported to bind as a receptor to trigger signaling cascades (7,8). Through both mechanisms, CD38 influences proliferation and trafficking (8,9). CD38 is used as a marker for poor prognosis in chronic lymphocytic leukemia and multiple myeloma and is an attractive cancer immunotherapy drug target (8-11).

References

  1. Schuber, F. and F.E. Lund (2004) Curr. Mol. Med. 4:249.
  2. Liu, Q. et al. (2005) Structure. 13:1331.
  3. Jackson, D.G. and J.I. Bell (1990) J. Immunol. 144:2811.
  4. Sun, L. et al. (1999) J. Cell Biol. 146:1161.
  5. Partida-Sanchez, S. et al. (2001) Nature Med. 7:1209.
  6. Kato, I. et al. (1995) J. Biol. Chem. 270:30045. 
  7. Deaglio, S. (2000) Chem. Immunol. 75:99.
  8. Chillemi,A. et al. (2013) Mol. Med. 19:99.
  9. Vaisitti, T. et al. (2015) Leukemia. 29:356.
  10. Atanackovic, D. et al. (2016) Oncoimmunology. 5:e1217374.
  11. Tai, Y-T. et al. (2017) Oncotarget. 8:112166.

Long Name

Cluster of Differentiation 38

Alternate Names

ADP-ribosyl Cyclase, CD38, Cyclic ADP-ribose Hydrolase

Entrez Gene IDs

952 (Human); 12494 (Mouse); 25668 (Rat); 102126394 (Cynomolgus Monkey)

Gene Symbol

CD38

UniProt

Additional CD38 Products

Product Documents for Recombinant Human CD38 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human CD38 Fc Chimera Protein, CF

For research use only

Loading...
Loading...
Loading...